Search Results

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device.

Attune Medical®, a pioneer in the field of esophageal temperature management with its ensoETM® device, is providing significant support for the upcoming AF Symposium as part of the company’s corporate mission.

Haemonetics Corporation announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures.

Attune Medical, a pioneer in utilizing the esophageal space to proactively manage patient temperature and to reduce the likelihood of esophageal injury during cardiac ablation procedures, announces significant growth with three key additions and expansion of commercial operations.

Bionomics Limited announced the release of the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder.

MCRA, LLC is pleased to announce its role in assisting Attune Medical with its De Novo marketing authorization from the US Food and Drug Administration (FDA) for the ensoETM™ device to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures.

Attune Medical has been granted De Novo marketing authorization from the US Food and Drug Administration (FDA) for its ensoETM device to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures.

Attune Medical and Heart Rhythm Clinical Research Solutions (HRCRS) are partnering on an evaluation of Attune’s ensoETM thermal regulating device through the HRCRS Real World Evidence (RWE) consortium.

Heart Rhythm Clinical and Research Solutions and the Real World Evidence Consortium have enrolled the first patient in the REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing study.